The video this transcript is based on appeared on December 19.
NEW YORK (TheStreet) -- Boston Therapeutics new PAZ320 tablet is designed to reduce a person's sugar intake before eating a meal.
Diabetes is a disease that is affecting millions and millions of Americans but there are some companies that are addressing the problems here and taking kind of a novel approach. One of those is Boston Therapeutics (BTHE) and I'm going to talk to the CEO Dr. David Platt. He has a couple of products and one is PAZ320 and it's a tablet that you take before you eat that reduces the amount of sugar your body absorbs and then another is Ipoxyn and it helps with problems such as foot ulcers. Dr. Platt, let's talk about the first one, the PAZ320. Everything we eat has sugar in it, just everything, so this tablet sounds like it's really gonna help that.
Dr. David Platt:
Absolutely, what we use is called a non-systemic approach. The other drugs, other diabetes drugs, are systemic, goes into the blood and operate only or activate mechanism in the body in the blood. What we do, we have a chemistry that blocks the enzyme in the intestine and as a consequence the sugar in the food is less digested. In our clinical trial we show forty percent reduction of the amount of sugar that goes into the blood. We actually don't reduce the sugar in the blood, we don't let it go up. And the sugar that is not digested by the enzyme goes out to the system.
Right, and if you've ever tried to eat less sugar you know it is almost impossible. Everything on the shelves has tons and tons of sugar in it. Another issue with diabetic patients, if you have friends or family with diabetes you know that these wounds, these problems that come as a result the disease. This drug Ipoxyn helps the healing in those wounds, right?
Dr. David Platt:
Ipoxyn is basically an anti-necrosis drug and it treats hypoxia or condition of lack of oxygen in the tissue. So [the] wound is usually started by a lack of oxygen. So it's an IV carbohydrate carry oxygenated, injected IV. It goes into the body, picks up an oxygen molecule in releasing next to the wound to treat the hypoxia condition called oxygen therapeutics.
Alright well these are two very fascinating new products. Now the PAZ320 is being tested now for use with other diabetes drugs but hopefully in the future it will get approved for all of us that want to reduce the amount of sugar in and have tried but but have a hard time doing so, not for diet, just truly for reducing the sugar that is absorbed in your body. That's doctor David Platt, his company is Boston Therapeutics, they're fairly new company traded over-the-counter, and I'm Debra Borchardt with TheStreet.
Written by Debra Borchardt in New York.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV